VANCOUVER, British Columbia and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering ...

Could inhaling xenon gas help fight Alzheimer’s disease? In the January 15 Science Translational Medicine, scientists led by Oleg Butovsky at Brigham and Women’s Hospital, Boston, and David Holtzman ...

Share on Pinterest Scientists are investigating xenon gas as a potential treatment for Alzheimer’s. Westend61/Getty Images Researchers continue to search for effective treatments for Alzheimer ...

Louis points to a novel-and noble-approach: using Xenon gas. The study found that Xenon gas inhalation suppressed neuroinflammation, reduced brain atrophy, and increased protective neuronal states ...

Xenon gas emerges as a promising treatment for Alzheimer’s, showing benefits in preclinical tests such as reducing brain atrophy and enhancing neuron protection, with human trials starting soon. A ...

Louis points to a novel—and noble—approach: using Xenon gas. The study found that Xenon gas inhalation suppressed neuroinflammation, reduced brain atrophy, and increased protective neuronal ...

The study found that Xenon gas inhalation suppressed neuroinflammation, reduced brain atrophy, and increased protective neuronal states in mouse models of Alzheimer's disease. A phase 1 clinical ...

The gas xenon, like the other noble, or inert, gases, is known for doing very little. The class of elements, because of its molecular structure, don’t typically interact with many chemicals.

Louis found Xenon gas inhalation reduced neurodegeneration and boosted protection in preclinical models of Alzheimer’s disease “It is exciting that in both animal models that model different a ...

And what could possibly be more earthy than the elements of the periodic table, which literally come from the earth itself? The vibe is 50% nature name, 50% science name … and 100% super-cool ...

Xenon Pharmaceuticals provided an update on its pipeline programs, highlighting significant progress and upcoming milestones for 2025. The company anticipates topline data from its first Phase 3 ...

Xenon Pharmaceuticals (XENE) outlined progress within its pipeline programs and key milestones for 2025. Phase 3 azetukalner clinical studies in focal onset seizures continue to advance, with the ...